SMC March Update
The Scottish Medicines Consortium has issued its monthly advice on new medicines.
Zoledronic acid infusion (Aclasta®) has been accepted for restricted use in patients who are unsuitable for or unable to tolerate oral treatment options for osteoporosis.
Salmeterol / fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler®) was rejected for the treatment of patients with chronic obstructive airways disease (COPD), with a forced expiration volume in 1 second (FEV1) 50 to <60% predicted normal. The manufacturer did not present a sufficiently robust economic case to gain acceptance.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected medicines should be avoided.
| « Script charge to rise in April | No Smoking Day » |
